Avelumab (Bavencio) plus best supportive care (BSC) as frontline maintenance therapy produced a favorable benefit-risk balance for Japanese patients with advanced urothelial cancer who did not progress on first-line chemotherapy, according to results of a subgroup analysis presented during the 2021 Genitourinary Cancers Symposium.1
Data from the phase 3 JAVELIN Bladder 100 trial (NCT02603432) showed that the median overall survival (OS) in the Japanese subset was 24.7 months (95% CI, 18.2–not estimable [NE]) with avelumab/BSC (n = 36) compared with 18.7 months (95% CI, 12.8-33.0) with BSC alone (n = 37; unstratified HR, 0.81; 95% CI, 0.41-1.58).
In Japanese patients with PD-L1–positive tumors, the median OS was 18.6 months (9.4–NE) and 19.4 months (95% CI, 11.7-33.0), respectively (HR, 1.00; 95% CI, 0.41-2.41). However, the 95% confidence intervals were wide due to the small number of…
